Pfizer jumped 5.24% to Rs 5267.90 after the company's parent said on Friday that its experimental Covid-19 antiviral pill cut by 89% the chance of hospitalization or death for adults at risk of severe disease.
The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe Covid-19 disease. The drug was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with Covid-19.In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo.
At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (USFDA), Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results and plans to submit the data as part of its ongoing rolling submission to the USFDA for Emergency Use Authorization (EUA) as soon as possible.
Pfizer's net profit rose 8.8% to Rs 142.95 crore on 6.8% increase in net sales to Rs 636.26 crore in Q2 FY22 over Q2 FY21.
Pfizer is a research-based global biopharmaceutical company which is engaged in the discovery, development and manufacture of healthcare products.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU